Illumina, Inc.
Health
Performance
6.0
Risk
Sell
Buy
Curious about the Scores? Learn more.

Illumina, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

15.01.2026
Signs of control returning. Still shaky, but not chaos.
10.01.2026
Momentum tanked. Clearly underperforming.
09.01.2026
Fragile setup. Still failing to meet the key marks today.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.

Illumina, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Illumina, Inc. do? Business model and key facts

Get the full picture of Illumina, Inc.: what it builds, where it operates, and how it makes money.

Illumina, Inc. Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 8970

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

shop
Company facts
Jacob Thaysen
CEO
8970
Employees worldwide
shop
Performance
6.69%
Last 12 months
-60.27%
Last 5 years
shop
Growth
$4,37B
Revenue year
$-1.223.000.000
Net income
shop
Valuation
$22,20B
Market Cap
-17.37
Price/Earnings Ratio

Stocks related to Illumina, Inc.

Selected based on industry alignment and relative market positioning.

WAT
Waters Corporation
394.59
+0.35%
5.5
Sell
Buy
Waters Corporation
MTD
Mettler-Toledo International Inc.
1,496.61
+0.74%
4.7
Sell
Buy
Mettler-Toledo International Inc.
NTRA
Natera, Inc.
240.34
+0.48%
6.7
Sell
Buy
Natera, Inc.
DGX
Quest Diagnostics Incorporated
190.26
+1.87%
2.1
Sell
Buy
Quest Diagnostics Incorporated
EXAS
Exact Sciences Corporation
102.34
+0.08%
6.8
Sell
Buy
Exact Sciences Corporation

Illumina, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.